Market closed
10x Genomics/$TXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Ticker
$TXG
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
1,306
ISIN
US88025U1097
Website
10x Genomics Metrics
BasicAdvanced
$1.2B
-
-$1.30
1.94
-
Price and volume
Market cap
$1.2B
Beta
1.94
52-week high
$28.25
52-week low
$6.78
Average daily volume
4M
Financial strength
Current ratio
5.373
Quick ratio
4.444
Long term debt to equity
9.992
Total debt to equity
11.328
Interest coverage (TTM)
-60,529.67%
Management effectiveness
Return on assets (TTM)
-12.43%
Return on equity (TTM)
-22.03%
Valuation
Price to revenue (TTM)
1.873
Price to book
1.67
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
26.375
Growth
Revenue change (TTM)
-0.13%
Earnings per share change (TTM)
-42.13%
3-year revenue growth (CAGR)
7.76%
3-year earnings per share growth (CAGR)
17.44%
What the Analysts think about 10x Genomics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
10x Genomics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
10x Genomics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
10x Genomics News
AllArticlesVideos
10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript
Seeking Alpha·6 days ago
10x Genomics: Lower Cost Innovation May Drive A Rebound
Seeking Alpha·2 months ago
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Benzinga·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 10x Genomics stock?
10x Genomics (TXG) has a market cap of $1.2B as of May 15, 2025.
What is the P/E ratio for 10x Genomics stock?
The price to earnings (P/E) ratio for 10x Genomics (TXG) stock is 0 as of May 15, 2025.
Does 10x Genomics stock pay dividends?
No, 10x Genomics (TXG) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next 10x Genomics dividend payment date?
10x Genomics (TXG) stock does not pay dividends to its shareholders.
What is the beta indicator for 10x Genomics?
10x Genomics (TXG) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.